When Weight Loss Becomes the Standard Again: GLP-1 Medications, Eating Disorders, and the Women Being Left Behind
Published June 30, 2026
By Cynthia Borozcky, MSW Candidate
Just a few years ago, the body positivity movement encouraged women to challenge unrealistic beauty standards and embrace body diversity. Social media feeds increasingly celebrated bodies of all sizes, conversations shifted toward health rather than weight, and many women found permission to step away from chronic dieting.
Today, that cultural shift appears to be changing.
The widespread availability and popularity of GLP-1 medications—including semaglutide and tirzepatide—has reignited society's longstanding obsession with thinness. As dramatic weight-loss stories dominate headlines and social media, many women are once again receiving the message that smaller bodies are more desirable, more disciplined, and somehow more worthy.
While GLP-1 medications can be life-changing for individuals with obesity and certain metabolic conditions, they also present important psychological considerations—particularly for individuals with current or past eating disorders.
A New Era of Weight Loss Pressure
GLP-1 receptor agonists work by slowing gastric emptying, increasing feelings of fullness, and reducing appetite. For many patients, these medications lead to substantial weight loss.
However, rapid weight loss has become highly visible and increasingly normalized. The cultural narrative has shifted from "love your body" to "why haven't you started a GLP-1?"
For women already navigating body image concerns, chronic dieting, or recovery from an eating disorder, this shift can be particularly harmful. Constant exposure to conversations about weight loss can reinforce the belief that thinner is always better—even when pursuing weight loss comes at the expense of mental health.
Eating Disorders Don't Disappear Because a Medication Exists
Eating disorders are complex mental health conditions—not simply problems with food or body weight.
Organizations such as the National Eating Disorders Association (NEDA) caution that GLP-1 medications may complicate recovery for individuals with eating disorders because appetite suppression and rapid weight loss can reinforce restrictive eating behaviors and make it more difficult to recognize relapse (National Eating Disorders Association [NEDA], 2026).
Clinicians have begun documenting these concerns in medical literature. In one published case report, an adolescent with atypical anorexia nervosa experienced worsening symptoms following treatment with semaglutide, highlighting the importance of careful screening and ongoing monitoring when prescribing these medications to vulnerable individuals (Liekens et al., 2025).
Experts interviewed by NPR similarly note that while GLP-1 medications may benefit some patients, they can intensify obsessive thoughts about food, encourage restrictive eating patterns, and complicate treatment for people living with anorexia nervosa, bulimia nervosa, binge eating disorder, or other forms of disordered eating (Noguchi, 2026).
Psychiatrist Susan Trachman (2026) further emphasizes that medications reducing appetite may inadvertently reinforce eating disorder behaviors by making restriction easier to maintain, potentially delaying recognition of worsening symptoms.
The Women We Don't See
One aspect of this conversation often receives far less attention: access.
GLP-1 medications remain prohibitively expensive for many individuals, particularly when insurance coverage is limited or unavailable. Women living in lower socioeconomic communities frequently face financial barriers that make these medications inaccessible.
This creates a troubling disparity.
Women with financial resources may have access to medications increasingly portrayed as the "solution" to weight concerns, while women without those resources continue facing the same societal pressure to lose weight—without access to the tools being marketed as the answer.
The result is a widening divide in both physical and mental health. Financial inequality becomes intertwined with body image, reinforcing stigma and increasing feelings of inadequacy among women already experiencing structural barriers to healthcare.
Weight stigma has never affected everyone equally. Now, access to weight-loss medication may become another marker of socioeconomic privilege.
A Trauma-Informed Perspective
At trauma-informed practices, we recognize that relationships with food and body image are rarely about willpower.
Many women have experienced years of dieting, weight stigma, adverse childhood experiences, chronic stress, medical trauma, or societal messages equating thinness with worth. For these individuals, conversations about GLP-1 medications cannot focus solely on pounds lost.
They must also include questions such as:
What is motivating the desire for weight loss?
Is there a history of disordered eating?
How might appetite suppression affect recovery?
What emotional needs are being met through body change?
How can treatment prioritize psychological well-being alongside physical health?
These are conversations deserving of nuance rather than judgment.
Supporting Health Without Reinforcing Harm
GLP-1 medications are neither inherently good nor inherently bad. For some individuals, they significantly improve health outcomes and quality of life.
However, as these medications become increasingly common, it is essential that mental health remains part of the conversation.
Women deserve healthcare that addresses the whole person—not simply a number on a scale.
Recovery means developing a relationship with food and one's body that is grounded in nourishment, flexibility, and self-compassion—not fear, restriction, or comparison.
As the cultural conversation around weight continues to evolve, protecting mental health should remain just as important as improving physical health.
References
Liekens, L., Kaïret, K., & Elst, E. F. (2025). Semaglutide-associated worsening of atypical anorexia nervosa in an adolescent girl: Case report. BJPsych Open, 12(1), e2. https://doi.org/10.1192/bjo.2025.10909
National Eating Disorders Association. (2026, May 26). GLP-1 medications and eating disorders. https://www.nationaleatingdisorders.org/glp-and-eating-disorders/
Noguchi, Y. (2026, February 4). GLP-1 obesity drugs can complicate life for people with disordered eating. NPR. https://www.npr.org/2026/02/04/nx-s1-5677633/glp-1-obesity-wegovy-zepbound-eating-disorders-anorexia-bulimia
Trachman, S. B. (2026, May 24). The risks of GLP-1 medications in patients with a history of eating disorders. Psychology Today. https://www.psychologytoday.com/us/blog/its-not-just-in-your-head/202605/the-thin-line-glp-1-drugs-and-the-rise-of-disordered-eating
